gracecast-099_lung-cancer_mm in lc pt 4: broadening use of markers in practice -- panel discussion
Published 12 years ago • 16 plays • Length 16:57Download video MP4
Download video MP3
Similar videos
-
17:28
gracecast-098_lung-cancer_mm in lc pt 3: who to test and what to test for -- panel discussion
-
24:30
gracecast-100_lung-cancer_mm in lc pt 5: dr. spigel on incorporating targets into clinical trials
-
17:36
gracecast-096_lung-cancer_mm in lc pt 1: dr. charles rudin on the lung cancer mutation consortium
-
5:17
immunotherapy in stage iii nsclc - case based panel discussion
-
2:30
advances in oligometastatic disease - onctalk lung 2023
-
6:00
perioperative keytruda for early stage nsclc-leading developments & current questions in lung cancer
-
2:45
lung cancer update
-
3:22
acquired resistance in lung cancer treatment - lcvl 2024
-
27:47
ret fusion-positive nsclc: delivering targeted treatment | panel discussion
-
10:49
gracecast-097_lung-cancer_mm in lc pt 2: dr. alice shaw on mutation patterns by patient features
-
6:30
stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
-
3:02
the future of ret nsclc treatment - targeted therapies in lung cancer 2023
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
1:59:57
grace - global resource for advancing cancer education live stream
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
6:52
safety and toxicity of selpercatinib versus pralsetinib - targeted therapies in lung cancer 2023
-
25:07
gracecast-101_lung-cancer_mm in lc pt6: dr. goss on incorporating markers across a hc system
-
0:13
the importance of biomarker testing- targeted therapies in lung cancer 2023- #shorts #youtubeshorts
-
13:44
gracecast-079_lung-cancer_challenging cases in lung cancer: unresectable locally advanced nsclc
-
8:20
case based panel discussion - egfr - progression, next steps - a place for chemo & immunotherapy? v2
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3